Gastrodia and Reduced Postoperative Delirium Incidence

Doses used in studies

mg/day: 1,200 (median 1,200, IQR 1,200–1,200) — 1 study

Time to effect

Median: 7 days · IQR 7 days–7 days · Range 7 days–7 days — Reported in 1 of 1 study

Safety in these studies

Overall tolerabilityReported
Adverse events occurred in 9.1% (7/77) of patients administered gastrodin and 14.1% (11/78) of patients administered the placebo, with none being drug-related.
from: Efficacy and safety of gastrodin in preventing postoperative delirium following cardiac su

1 of 1 paper

Efficacy and safety of gastrodin in preventing postoperative delirium following cardiac surgery: a randomized placebo controlled clinical trial.

2025-03-11
RCT
Critical care (London, England) 29(1)
- Yun-Xiao Bai
- Hui-Liang Wu
- Wan-Li Xie
- Xia Li
- Jing-Jing Han
- Jie Liu
- Shi-Qiang Chen
- Ping Yin
- Nian-Guo Dong
- Qing-Ping Wu

PubMed: 40069830
DOI: 10.1186/s13054-025-05331-9

3 Insights on

Reduced Postoperative Delirium Incidence

High evidence
Clinical

The incidence of postoperative delirium was 19.5% in the gastrodin group and 35.9% in the placebo group, with a significant relative risk of 0.54 (95% CI 0.32-0.93, p=0.022).

Effect: Beneficial
Effect size: Large
Significant: Yes
Dose: 600 mg twice daily